<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369352</url>
  </required_header>
  <id_info>
    <org_study_id>AGO R03 ROC</org_study_id>
    <nct_id>NCT04369352</nct_id>
  </id_info>
  <brief_title>Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria</brief_title>
  <official_title>Non-interventional, Multicenter, Prospective Register Study to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (ROC) Patients in Austria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various treatment options exist for patients with platinum-sensitive relapsed epithelial
      ovarian cancer (ROC).

      The register will provide an overview of chosen treatments including the reasons, why these
      options were chosen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients at their first platinum-sensitive ROC will be invited to participate in the
      register.

      These are all patients with recurrent disease 6 or more months after the last cycle of
      platinum containing chemotherapy.

      The Observation Period will begin by signing the Informed Consent Form (ICF) and will
      continue for up to a total of 24 months (+/- 4 weeks) after the diagnosis of the first
      relapse or until patient discontinuation for any reason, or patient's death.

      Data on First Study Visit, Subsequent Recurrence during Observation Period and Last
      Observation will be collected in the electroinic Case Report Form (eCRF).

      The register will identify symptoms and factors that led to the diagnosis, chosen therapy and
      the reason for choosing the therapy. At inclusion, data on general patient information,
      primary diagnosis, previous therapy, and tumor characteristics are collected. During the
      course of observation data on systemic and maintenance treatments, radiotherapies, surgeries,
      and outcome are documented.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>To assess treatment patterns and the reasons for selecting these treatments in patients with platinum-sensitive ROC after first relapse in Austria</measure>
    <time_frame>Two years</time_frame>
    <description>Descriptive Data Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years per patient</time_frame>
    <description>after first relapse and second relapse, evaluated by clinical practice in each center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years per patient</time_frame>
    <description>at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Treatments</measure>
    <time_frame>2 years per patient</time_frame>
    <description>treatment duration, number of cycle, treatment exposure, time to next treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Description</measure>
    <time_frame>2 years per patient</time_frame>
    <description>died due to disease, died due to other reasons, alive</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at their first platinum-sensitive ROC treated within gynecological oncology
        centers in Austria participating in the register.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 years or older

          -  Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube
             cancer)

          -  Must have received at least 4 cycles of chemotherapy during primary therapy

          -  At time of inclusion a treatment for ROC must be planned

          -  Patients must not have more than 1 prior line of chemotherapy

          -  Signed informed consent

        Exclusion Criteria:

          -  No knowledge of spoken and written German

          -  Signed informed consent is not given
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Hefler, Prim. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ordensklinikum Linz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AGO Studienzentrale</last_name>
    <phone>0043 512 504 24132</phone>
    <email>ago.studienzentrale@i-med.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Petru, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Marth, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Heider, Prim. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Hochsteiermark</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florentia Peintinger, Prof. PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Lienz</name>
      <address>
        <city>Lienz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Volgger, Prim. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universit√§tsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Angleitner-Boubenizek, OA Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Hefler, Prim. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Ried</name>
      <address>
        <city>Ried Im Innkreis</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Baminger, OA Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Reinthaller, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

